Chemotherapy-Induced Nausea and Vomiting

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

AKYNZEOApproved

netupitant and palonosetron

Helsinn

Serotonin-3 Receptor Antagonist [EPC]oral2014

5M Part D

EMENDApproved

fosaprepitant dimeglumine

Merck & Co.

intravenous2008

62K Part D

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

MSDIreland - Ballydine

14 programs

Fosaprepitant DimegluminePhase 41 trial

FosaprepitantPhase 31 trial

aprepitantPhase 31 trial

AprepitantPhase 21 trial

Aprepitant/Ramosetron/DexamethasonePhase 21 trial

+9 more programs

Active Trials

NCT01074255Completed3,546Est. Oct 2011

NCT00990821Completed188Est. Jan 2006

NCT00971633Completed12Est. Jan 2004

+11 more trials

Sharp TherapeuticsPA - Pittsburgh

14 programs

Fosaprepitant DimegluminePhase 4

FosaprepitantPhase 3

aprepitantPhase 3

AprepitantPhase 2

Aprepitant/Ramosetron/DexamethasonePhase 2

+9 more programs

HelsinnIreland - Dublin

9 programs

NEPAPhase 41 trial

Netupitant and PalonosetronPhase 3

Oral palonosetronPhase 3

PalonosetronPhase 31 trial

+4 more programs

Active Trials

NCT03668639Unknown80Est. Apr 2023

NCT02557035Completed441Est. Mar 2016

NCT01442376Completed502Est. Nov 2012

+3 more trials

Merck & Co.RAHWAY, NJ

4 programs

90 mg MK-0517PHASE_1

Comparator: Treatment APHASE_1

ondansetron clinical trial formulationPHASE_1

FosaprepitantPHASE_2

UNION therapeuticsDenmark - Hellerup

1 program

Aprepitant+palonosetron+dexamethasonePhase 31 trial

Active Trials

NCT02933099Unknown300Est. Dec 2018

Solasia Pharma K.K.Japan - Tokyo

1 program

SP-01Phase 31 trial

Active Trials

NCT01937156Completed313Est. Feb 2014

Taiho PharmaJapan - Tokyo

1 program

palonosetronPhase 31 trial

Active Trials

NCT00359567Completed1,140Est. Aug 2007

Acacia PharmaUK - Cambridge

1 program

APD421Phase 21 trial

Active Trials

NCT01303978Completed51Est. Jul 2012

ParexelMA - Boston

3 programs

Netupitant and PalonosetronPHASE_31 trial

Oral palonosetronPHASE_31 trial

Active Trials

NCT01376297Completed413

NCT01339260Completed1,455

NCT01363479Completed743Est. Nov 2012

Heron TherapeuticsNC - Cary

2 programs

GRANISETRON EXTENDED RELEASE INJECTIONPHASE_21 trial

APF530PHASE_31 trial

Active Trials

NCT04085393Withdrawn0Est. Dec 2022

NCT02106494Completed942Est. May 2015

Purdue PharmaCT - Stamford

1 program

300mg netupitant/0.5mg palonosetron hydrochlorideN/A1 trial

Active Trials

NCT03649230Completed207Est. Jan 2020

Otolith LabsDC - Washington

1 program

OtobandN/A1 trial

Active Trials

NCT03996863Withdrawn0Est. Aug 2019

Applied MedicalCA - Rancho Santa Margarita

1 program

Prevalence of Delayed Chemotherapy Associated NauseaN/A1 trial

Active Trials

NCT04342780Completed172Est. May 2022

Qilu PharmaceuticalChina - Jinan

1 program

QLM2010 for injection；dexamethasonePHASE_31 trial

Active Trials

NCT07081256Completed665Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

HelsinnNEPA

MSDFosaprepitant Dimeglumine

Qilu PharmaceuticalQLM2010 for injection；dexamethasone

Helsinnfosnetupitant/ palonosetron

UNION therapeuticsAprepitant+palonosetron+dexamethasone

HelsinnPro-netupitant/Palonosetron

HelsinnPalonosetron

MSDFosaprepitant

Heron TherapeuticsAPF530

Solasia Pharma K.K.SP-01

HelsinnPalonosetron

ParexelNetupitant and Palonosetron

ParexelOral palonosetron

ParexelNetupitant and Palonosetron

MSDaprepitant

Showing 15 of 33 trials with date data

Clinical Trials (33)

Total enrollment: 14,085 patients across 33 trials

NCT04817189 HelsinnNEPA

Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

Start: Feb 2021Est. completion: Jul 2024414 patients

Phase 4Completed

NCT04054193 MSDFosaprepitant Dimeglumine

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Start: Sep 2019Est. completion: Feb 2021103 patients

Phase 4Completed

NCT07081256 Qilu PharmaceuticalQLM2010 for injection；dexamethasone

To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

Start: Jan 2025Est. completion: Oct 2025665 patients

Phase 3Completed

NCT03403712 Helsinnfosnetupitant/ palonosetron

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

Start: Mar 2018Est. completion: Sep 2018404 patients

Phase 3Completed

NCT02933099 UNION therapeuticsAprepitant+palonosetron+dexamethasone

Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting

Start: Oct 2016Est. completion: Dec 2018300 patients

Phase 3Unknown

NCT02517021 HelsinnPro-netupitant/Palonosetron

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

Start: Nov 2015Est. completion: Aug 2016405 patients

Phase 3Completed

NCT02557035 HelsinnPalonosetron

An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting

Start: Oct 2015Est. completion: Mar 2016441 patients

Phase 3Completed

NCT02519842 MSDFosaprepitant

Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

Start: Sep 2015Est. completion: Feb 201775 patients

Phase 3Terminated

NCT02106494 Heron TherapeuticsAPF530

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

Start: Mar 2014Est. completion: May 2015942 patients

Phase 3Completed

NCT01937156 Solasia Pharma K.K.SP-01

A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting

Start: Aug 2013Est. completion: Feb 2014313 patients

Phase 3Completed

NCT01442376 HelsinnPalonosetron

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

Start: Sep 2011Est. completion: Nov 2012502 patients

Phase 3Completed

NCT01376297 ParexelNetupitant and Palonosetron

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Start: Jul 2011413 patients

Phase 3Completed

NCT01363479 ParexelOral palonosetron

An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting

Start: Jul 2011Est. completion: Nov 2012743 patients

Phase 3Completed

NCT01339260 ParexelNetupitant and Palonosetron

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Start: Apr 20111,455 patients

Phase 3Completed

NCT00337727 MSDaprepitant

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

Start: Jan 2007Est. completion: Nov 2008848 patients

Phase 3Completed

NCT00359567 Taiho Pharmapalonosetron

Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy

Start: Jul 2006Est. completion: Aug 20071,140 patients

Phase 3Completed

NCT03668639 HelsinnAkynzeo

Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Start: Sep 2018Est. completion: Apr 202380 patients

Phase 2/3Unknown

NCT04085393 Heron TherapeuticsGRANISETRON EXTENDED RELEASE INJECTION

Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting

Start: Aug 2020Est. completion: Dec 20220

Phase 2Withdrawn

NCT02445872 MSDAprepitant

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Start: Dec 2015Est. completion: May 201680 patients

Phase 2Unknown

NCT01874119 MSDFosaprepitant

Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma

Start: Sep 2013Est. completion: Dec 201513 patients

Phase 2Terminated

NCT01736917 MSDFosaprepitant

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

Start: Jan 2013Est. completion: Jun 201565 patients

Phase 2Completed

NCT01697579 MSDFosaprepitant

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)

Start: Dec 2012Est. completion: Nov 2016240 patients

Phase 2Completed

NCT01303978 Acacia PharmaAPD421

Phase II Proof-of-concept Study of APD421

Start: Feb 2011Est. completion: Jul 201251 patients

Phase 2Completed

NCT01012336 MSDAprepitant/Ramosetron/Dexamethasone

Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin

Start: May 2010Est. completion: Apr 201289 patients

Phase 2Completed

NCT00818259 MSDExperimental: aprepitant

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)

Start: Feb 2009Est. completion: Jan 201492 patients

Phase 1Terminated

NCT00945321 MSDaprepitant 165 mg

A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

Start: Feb 2009Est. completion: Mar 200942 patients

Phase 1Completed

NCT00990821 MSD90 mg MK-0517

A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)

Start: Jan 2005Est. completion: Jan 2006188 patients

Phase 1Completed

NCT00972595 MSDondansetron clinical trial formulation

Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)

Start: Jun 2004Est. completion: Sep 200445 patients

Phase 1Completed

NCT00971633 MSDComparator: Treatment A

A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)

Start: Nov 2003Est. completion: Jan 200412 patients

Phase 1Completed

NCT04342780 Applied MedicalPrevalence of Delayed Chemotherapy Associated Nausea

Prevalence of Delayed Chemotherapy Associated Nausea

Start: Jun 2020Est. completion: May 2022172 patients

N/ACompleted

NCT03996863 Otolith LabsOtoband

Prevention of Unmitigated Chemotherapy-induced Emesis

Start: Aug 2019Est. completion: Aug 20190

N/AWithdrawn

NCT03649230 Purdue Pharma300mg netupitant/0.5mg palonosetron hydrochloride

Observational Study on the Use of Akynzeo® in Patients Receiving HEC

Start: Oct 2018Est. completion: Jan 2020207 patients

N/ACompleted

NCT01074255 MSDEMEND

Re-examination Study of EMEND (Aprepitant) (MK-0869-184)

Start: Apr 2007Est. completion: Oct 20113,546 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

14 late-stage (Phase 3) programs, potential near-term approvals

14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.